A Multiplex Biomarker Assay Improves the Prediction of Survival in Epithelial Ovarian Cancer

• Published in: Cancer genomics & proteomics Vol. 20; no. 3; pp. 273 - 280
• Main Authors: Dobilas, Arturas, Åkesson, Anna, Leandersson, Pia, Borgfeldt, Christer
• Format: Journal Article
• Language: English
• Published: Greece International Institute of Anticancer Research 01.05.2023
• Subjects: Age; Antigens; Biomarkers; Biomarkers, Tumor; Cancer; Carcinoma, Ovarian Epithelial - pathology; Chemokines; Epididymis; Female; Glycoproteins; Humans; Leukemia; Lymphocytes T; Lymphoma; Membrane Glycoproteins; Neoplasms, Glandular and Epithelial; Neurotrophin 3; Ovarian cancer; Ovarian Neoplasms - pathology; Performance evaluation; Peripheral blood; Prediction models; Proteins; Proteins - metabolism; Proteomics; Regression analysis; Survival; overall survival; biomarker; Epithelial ovarian cancer
• ISSN: 1109-6535; 1790-6245
• DOI: 10.21873/cgp.20380

Epithelial ovarian cancer (EOC) is usually diagnosed in advanced stages and has a high mortality rate. In this study, we used the proximity extension assay from Olink Proteomics to search for new plasma protein biomarkers to predict overall survival (OS) in patients with EOC. Peripheral blood samples were obtained preoperatively from 116 EOC patients undergoing primary debulking surgery: 28 early EOC cases (FIGO stage I-II) and 88 advanced EOC cases (FIGO stage III-IV). Proteins were measured using the Olink Oncology II and Inflammation panels. In total, 177 unique protein biomarkers were analysed. Cross-validation and LASSO regression were combined to select prediction models for OS. The model including age and the three-biomarker combination of neurotrophin-3 (NT-3)+transmembrane glycoprotein NMB (GPNMB)+mesothelin (MSLN) predicted worse OS with AUC=0.79 (p=0.004). Adding cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) to the model further improved performance (AUC=0.83; p=0.003). In a postoperative model including age and stage (III+IV vs. I+II), the three-biomarker panel of chemokine (C-C motif) ligand 28 (CCL28)+T-cell leukaemia/lymphoma protein 1A (TCL1A)+GPNMB improved the prediction of OS (from AUC=0.83 to AUC=0.90; p=0.05). In the postoperative model including age and dichotomized stage (III vs. I+II), the biomarkers CCL28 and GPNMB1 improved the prediction of OS (AUC=0.86; p<0.001). The combination of high levels of both CA125 and HE4 predicted worse survival (p=0.05). In this explorative study evaluating the performance of plasma protein biomarkers in predicting OS, we found that adding biomarkers, especially NT-3, to the panel improved the prediction of OS.